A mitochondrial inhibitor shifted glioblastoma metabolism on MRI — but the survival benefit was not significant, in mice

Edited by Samael A. Tejada, Founder & Editor-in-Chief

This is the kind of result that separates a metabolic effect from a treatment. The scans moved; the survival curves did not — significantly, at least — and the authors published both, which is exactly how preclinical cancer research should read.

Why target tumour metabolism at all?

Resistance to temozolomide limits glioblastoma treatment, and that resistance is fuelled by metabolic reprogramming — cancer cells rewiring how they make energy — plus changes in the tumour microenvironment. Lactate, long treated as a waste product of glycolytic cancer cells, is now understood to shape that microenvironment. Lonidamine, a glycolytic and mitochondrial inhibitor, modulates tumour metabolism and can alter how tumours respond to treatment, which is why the Liverpool team paired it with temozolomide and watched with metabolic imaging.

What did the imaging show?

A significant decrease in lactate in the lonidamine and combination groups indicated a smaller steady-state lactate pool — reduced production, altered utilization or changed glycolytic flux — while lactate stayed high in the control and temozolomide-only groups. The shift matched a marked reduction in MCT4, the lactate transporter protein, in lonidamine-treated tumours. In vitro, Seahorse bioenergetic profiling of GL261 cells showed an acute decrease in mitochondrial respiration in response to lonidamine, with partial recovery at later time points — a hint that the metabolic pressure is strongest early.

What did not improve?

The endpoints a patient would care about. The enhanced survival benefit of the combination was, in the authors' words, not significant; tumour volume, diffusion-weighted imaging parameters and mitotic index showed no significant differences between groups after six days. The authors' own conclusion is calibrated: lonidamine induces early metabolic changes detectable by MR spectroscopy, its tumour-selective activity is promising, and its long-term effects should be investigated as part of an optimized combination strategy. That is a biomarker-and-rationale paper — valuable, and importantly not a claim that the drug combination works.

Where the evidence stands

• Established: Temozolomide resistance and metabolic reprogramming are central problems in glioblastoma, and MR spectroscopy can non-invasively track tumour lactate.
• Preliminary: Lonidamine's metabolic effect in this model (lactate and MCT4 down, respiration acutely down) — one mouse study with a short, five-day treatment window.
• Absent: A significant survival or tumour-volume benefit in this study, and any human evidence for the combination.